Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oxycodone prodrug activation (trypsin-mediated) is a drug delivery strategy employing trypsin, a serine protease primarily in the small intestine, to activate inactive oxycodone prodrugs. This approach aims to improve the safety profile and reduce misuse risk compared to immediate-release opioids by releasing oxycodone primarily in the small intestine after oral administration. The prodrug undergoes proteolytic cleavage by trypsin, followed by intramolecular cyclization, to release active oxycodone.
Proteolytic cleavage by trypsin followed by intramolecular cyclization, resulting in oxycodone release.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oxycodone Prodrug Activation (Trypsin-Mediated).